Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2023

(Commission File No. 001-40241)

---

LAVA Therapeutics N.V.

(Translation of registrant’s name into English)

---

Yalelaan 62

3584 CM Utrecht, The Netherlands

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒ Form 40-F  ☐

​

​

​

​

---

LAVA Therapeutics, N.V.

​

​

EXHIBIT LIST

Exhibit		Description
99.1	​	LAVA Therapeutics, N.V. Investor Presentation
​	​	​

​

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​	​	​
​	LAVA Therapeutics, N.V.
​	(Registrant)
​	​	​
Date: April 24, 2023	By:	/s/ Fred Powell
​	Fred Powell
​	Chief Financial Officer

​

---